Transformative Advances This Year and Beyond

This year marked a transformative period, defined by a series of groundbreaking FDA approvals that expanded treatment options across a wide range of skin conditions. From chronic spontaneous urticaria and atopic dermatitis to psoriasis, bullous pemphigoid, and rare genetic disorders, new therapies reflected a decisive shift toward precision medicine and targeted biologic or gene-based approaches. These innovations not only improved clinical outcomes but also prioritized patient comfort, safety, and long-term disease control. As the dermatologic pipeline continues to grow, the approvals of 2025 set a strong precedent for a new era of personalized and effective skin health management.

2025 Approvals

April 18: Dupilumab for Adolescents and Adults With H1 Antihistamine–Refractory CSU

The FDA approved dupilumab (Dupixent; Regeneron Pharmaceuticals and Sanofi) for the treatment of chronic spontaneous urticaria (CSU) in patients 12 years and older who remain uncontrolled on H1 antihistamines—the first new targeted therapy for CSU in more than a decade. The approval was supported by data from the phase 3 LIBERTY-CSU CUPID study program, in which dupilumab significantly improved itch and hive severity and nearly doubled rates of well-controlled disease compared with placebo.¹

April 29: First Gene Therapy for RDEB

Prademagene zamikeracel (pz-cel; Zevaskyn; Abeona Therapeutics), the first autologous, cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), was approved in April, marking a major advance in regenerative dermatology. Pz-cel is created from a patient’s own skin cells, genetically corrected ex vivo with a functional COL7A1 gene, and applied as cell sheets to chronic wounds, promoting durable collagen VII expression and wound healing after a single surgical procedure. Data from the phase 3 VIITAL study (NCT04227106) demonstrated significant and sustained wound closure, lasting up to 8 years in some patients, with a favorable long-term safety profile.²

May 16: LED BLU-U Device for AK

In May, the FDA approved Sun Pharmaceutical’s next-generation LED BLU-U Blue Light Photodynamic Therapy Illuminator for use with aminolevulinic acid hydrochloride 20% (Levulan Kerastick) in treating minimally to moderately thick actinic keratoses (AKs) on the face, scalp, and upper extremities. The updated model replaces fluorescent tubes with LED technology, offering improved light uniformity, a compact 5-panel design, and enhanced ergonomic functionality while maintaining the same clinical mechanism: photoactivation of aminolevulinic acid to induce localized cytotoxic effects and lesion clearance.³

May 22: Roflumilast Foam for Plaque Psoriasis

The approval of roflumilast 0.3% foam (Zoryve; Arcutis Biotherapeutics) for plaque psoriasis of the scalp and body in patients 12 years and older came this year, marking the first and only branded topical foam for psoriasis. This once-daily, steroid-free PDE4 inhibitor offers rapid symptom relief, with pivotal trials (phase 3 ARRECTOR [NCT05028582]) demonstrating that up to 63% of patients achieved significantly clear skin by 8 weeks, along with early itch improvement within 24 hours. The foam formulation is designed for hair-bearing and sensitive areas, minimizing irritants while maintaining high potency, and is generally well tolerated.⁴

June 20: Dupilumab for Bullous Pemphigoid

Also approved this year, dupilumab (Dupixent; Regeneron Pharmaceuticals and Sanofi) for the treatment of adults with bullous pemphigoid represented the first targeted therapy for this autoimmune blistering disease. The approval was based
on results from the phase 2/3
LIBERTY-BP (NCT04206553) trial, in which dupilumab plus tapering oral corticosteroids led to higher rates of sustained disease remission (18.3% vs 6.1% with placebo), meaningful itch reduction (38.3% vs 10.5%), and reduced cumulative corticosteroid use over 36 weeks.⁵

July 23: Delgocitinib for Adults With Moderate to Severe CHE

Another groundbreaking approval was for delgocitinib cream (Anzupgo; LEO Pharma), representing the first treatment for adults with moderate to severe chronic hand eczema (CHE) who have not responded to topical corticosteroids or for whom steroids are unsuitable. This topical pan–Janus kinase (JAK) inhibitor demonstrated efficacy in the phase 3 DELTA 1 (NCT04871711) and DELTA-2 trials (NCT04872101), with 20% to 29% of patients achieving clear or almost clear skin vs 7% to 10% on vehicle, along with meaningful reductions in pain and itch. Long-term data from the DELTA 3 (NCT04949841) extension trial showed durable responses, favorable tolerability, and rapid recapture of disease control upon retreatment.⁶

September 18: Ruxolitinib Cream for Pediatric AD

The FDA approved ruxolitinib cream (Opzelura; Incyte) for children aged 2 to 11 years with mild to moderate atopic dermatitis (AD), making it the first topical JAK inhibitor available for this pediatric population. The approval was supported by the phase 3 TRuE-AD3 (NCT04921969) trial, in which ruxolitinib cream demonstrated significant efficacy, with Investigator Global Assessment treatment success achieved in 36% to 57% of patients vs 11% with vehicle, rapid itch relief within 2 weeks, and improvements in quality-of-life measures. The cream was well tolerated, with mostly mild application site reactions and no systemic safety signals associated with oral JAK inhibitors.⁷

September 29: Guselkumab for Pediatric PsO and PsA

Guselkumab (Tremfya; Johnson & Johnson) received FDA approval for pediatric patients 6 years and older (≥40 kg) with moderate to severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA), marking the first pediatric approval of an IL-23 inhibitor for these conditions. The decision was supported by the phase 3 PROTOSTAR (NCT03451851) study, in which guselkumab demonstrated high efficacy, with 56% of patients achieving 90% improvement in the Psoriasis Area and Severity Index and nearly 40% achieving complete skin clearance at week 16 compared with 16% and 4% for placebo, respectively.⁸

September 30: Remibrutinib for CSU

In September, the FDA approved remibrutinib (Rhapsido; Novartis), an oral Bruton tyrosine kinase inhibitor (BTKi), for adults with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamines, marking the first BTKi approved for this condition. Remibrutinib works by selectively inhibiting BTK, reducing mast cell–mediated histamine release and other inflammatory mediators, and may also modulate autoimmune pathways in certain patients with CSU. Phase 3 REMIX-1 (NCT05030311) and REMIX-2 (NCT05032157) trials showed rapid and significant improvements in itch, hives, and urticaria activity scores, with approximately one-third of patients achieving complete symptom resolution by week 12.⁹

October 6: Roflumilast for AD as Young as 2 Years

Kicking off October, the FDA gave the green light to roflumilast cream 0.05% (Zoryve; Arcutis Biotherapeutics) for children aged 2 to 5 years with mild to moderate atopic dermatitis, offering a steroid-free, once-daily topical treatment for long-term management of pediatric eczema. Clinical trials (INTEGUMENT-PED [NCT04845620] and INTEGUMENT-OLE [NCT04804605]) demonstrated rapid improvement in eczema severity and itch, with approximately 40% of children achieving a 75% reduction in disease signs and more than one-third reporting meaningful itch relief within 4 weeks.¹⁰

October 13: Cemiplimab as Adjuvant Immunotherapy for High-Risk CSCC

Finally, the FDA granted approval to cemiplimab-rwlc (Libtayo; Regeneron Pharmaceuticals) as an adjuvant therapy for adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation, marking the first immunotherapy authorized in this setting.¹ The approval is supported by phase 3 C-POST (NCT03969004) trial data, which showed cemiplimab reduced the risk of disease recurrence or death by 68% compared with placebo, with 24-month disease-free survival rates of 87.1% vs 64.1% and significant reductions in locoregional and distant recurrence.¹¹

2026/What to Watch

Atopic Dermatitis (AD)

AD remains a hotbed of innovation, with multiple targeted therapies advancing through late-phase trials:

CGB-500 (CAGE Bio): Strong phase 2b efficacy reported, continuing to position IL-22 inhibition as a viable AD strategy.

“Topicals are essential in proper patient care. We want to give you highly effective topical products so you can reserve systemic drugs for those cases where localized treatment is not practical.” —Nitin Joshi, PhD, CEO and cofounder of CAGE Bio¹²

Amlitelimab (Sanofi): OX40L blockade demonstrates positive phase 3 results, reinforcing T-cell costimulation as a key therapeutic axis.

Rocatinlimab (Amgen; Kyowa Kirin):Maintains favorable safety profile in 24-week study.

STAR-0310 (Astria Therapeutics):Long-acting OX40 antagonist shows promising phase 1a data.

Rezpegaldesleukin (Rezpeg; NKTR-358; Nektar Therapeutics): Represents a first-in-class immunomodulatory approach.

“The FDA realizes that the unique mechanism of action of Rezpeg...really could push the envelope.” —Jonathan Zalevsky, PhD, chief of research and development at Nektar Therapeutics¹³

BBT001 (Bambusa Therapeutics):Dual IL-4Rα/IL-31 blockade moving into patient trials, aiming to tackle pruritus and inflammation simultaneously.

SYX-5219 (Sitryx): Oral therapy cleared for IND, highlighting the shift toward convenient, systemic options.

Alopecia Areata (AA) and Androgenetic Alopecia (AGA)

Pipeline activity suggests an expanding arsenal for hair disorders:

Bempikibart (Q32 Bio) and Rezpegaldesleukin (Nektar Therapeutics): Both AA therapies received FDA fast track designation, focusing on targeted immune modulation.

“The fast track designation granted by the FDA recognizes the seriousness of AA and the significant current unmet medical need while underscoring bempikibart’s potential as a novel, differentiated therapy for patients needing new options. We look forward to continued collaboration with the FDA as we work to deliver this potentially paradigm-shifting treatment to patients.” —Jodie Morrison, CEO of Q32 Bio¹⁴

Upadacitinib (AbbVie) and Ritlecitinib (Pfizer): Strong efficacy in pivotal phase 3 AA trials; oral JAK inhibition continues to lead.

Baricitinib (Olumiant):Demonstrates significant hair regrowth in adolescents.

“For nearly half of the people with severe [AA], the disease starts before adulthood and can progress quickly, significantly impacting patients’ lives.” —Nicole Friedland, president and CEO of the National Alopecia Areata Foundation¹⁵

PP405 (Pelage) and extended-release minoxidil: Show early promise in AGA, highlighting the combination of convenience and efficacy.

Hidradenitis Suppurativa (HS)

HS pipelines are emphasizing immune and complement pathways:

Brivekimig (Sanofi) and Povorcitinib (Incyte): Show sustained efficacy through 24-week phase 2a studies.

“HS remains a challenging and often debilitating condition, and many patients are in need of new, well-tolerated, and effective therapies that address prominent signs and symptoms of the disease, including inflammatory lesions and pain. The STOP-HS abstract will provide additional detail on povorcitinib as an oral treatment option for HS and its ability to rapidly improve symptoms, with continued clinical responses seen through 24 weeks.” —Pablo J. Cagnoni, MD, president and head of research and development at Incyte¹⁶

Sonelokimab (MoonLake Immunotherapeutics):Dual phase 3 data reinforce anti-inflammatory potential.

AVTX-009 (Avalo Therapeutics): Phase 2 enrollment completed, further expanding IL-targeted options.

“We are encouraged by the strong investigator and patient engagement in this trial, which reflects the high unmet need that exists for people living with HS. With AVTX-009’s high-affinity inhibition of IL-1β, we believe we are one step closer to offering a differentiated—potentially best-in-disease— treatment option for patients [with] this chronic and painful condition.” —Garry Neil, MD, CEO of Avalo Therapeutics¹⁷

INF904 (InflaRx):Oral C5aR inhibitor with early efficacy in HS and chronic spontaneous urticaria, highlighting complement-targeted strategies.

Psoriatic Disease

Multiple novel agents are targeting cytokine, TYK2, and PDE4 pathways:

AX-158 (Artax Biopharma) and AC-201 (Accro Bioscience): Phase 2 results show promise in plaque psoriasis.

ASC50 (Ascletis Pharma): Novel oral IL-17 inhibitor cleared for phase 1.

“The IND clearance of ASC50 marks a new milestone for Ascletis in autoimmune and inflammatory diseases. We are continuing to work on differentiated agents, including oral drugs and once-monthly or less frequent subcutaneously injectables to address unmet medical needs in multiple key therapeutic areas.”—Jason Wu, PhD, founder, chairman, and CEO of Ascletis Pharma¹⁸

Zasocitinib (Takeda Pharmaceuticals): Avoids JAK1/2/3 inhibition, offering a safer systemic profile.

Tildrakizumab (Sun Pharma): Positive phase 3 trial in psoriatic arthritis confirms TNF/IL-23 targeting.

ME3183 (Meiji Seika Pharma): PDE4 inhibitor effective in phase 2 psoriasis trial.

Envudeucitinib (Alumis) and Icotrokinra (Johnson & Johnson): Sustained efficacy in moderate to severe disease, including challenging areas.

“TYK2 inhibitors have really changed the landscape in terms of our management of patients with psoriasis. These medications provide meaningful response rates for patients with moderate to severe psoriasis vulgaris, including in difficult-to-treat regions such as the scalp, palms, and soles.” —Benjamin Lockshin, MD, board-certified dermatologist in Rockville, MD, and director of Clinical Trials Center at US Dermatology Partners¹⁹

ORKA-001 (Oruka Therapeutics): Moving toward yearly dosing, highlighting convenience for long-term disease control.

Rare Diseases

Orphan-focused therapies are advancing:

Dusquetide (Soligenix): Orphan designation for Behçet disease.

TAMES-02 (TolaSure; BioMendics):Epidermolysis bullosa simplex trial progressing, offering hope for blistering disorders.

“TolaSure is a topical therapy, which makes safety a key advantage. We’ve tested it in over 100 people across different trials and applications. Topicals are more approachable for patients—if there’s a reaction, you can simply discontinue. To potentially achieve disease-modifying effects with a topical is very exciting.” —Karen McGuire, PhD, CEO and cofounder of BioMendics²⁰

QRX003 (Quoin Pharmaceuticals):FDA orphan status for Netherton syndrome.

Skin Cancer

Immunotherapy and noninvasive interventions are moving forward:

Vidutolimod combination therapy (Regeneron Pharmaceuticals):Shows promise in advanced melanoma.

“For PD-1 blockade–resistant melanoma, new immunotherapy combinations are needed to simultaneously target multiple cancer immune evasion mechanisms.” —Milhem et al²¹

Eftilagimod alfa (Immutep): Patients with head and neck squamous cell carcinoma with low PD-L1 expression may benefit from LAG3 modulation.

D-MNA (Medicus Pharma): Noninvasive, novel basal cell carcinoma (BCC) therapy enters United Arab Emirates trials.

“Our interim findings confirm that our novel therapy is a viable commercial product in development that can become the first-in-class as well as the best-in-class noninvasive treatment alternative for BCC.” —Raza Bokhari, MD, CEO of Medicus Pharma²²

RP1 for advanced melanoma (Replimune Group):FDA biologics license application resubmission is accepted, maintaining momentum for intralesional viral therapies.

Vitiligo

Ritlecitinib plus narrowband UV-B
(nbUV-B; Pfizer): Accelerates repigmentation in nonsegmental vitiligo.

“Combination therapy with nbUV-B is expected to expedite the response because the immunomodulators are thought to affect step 1 therapy, and the phototherapy would contribute to the second step. The increased interest in the combination therapy is also based on preliminary data showing that the novel immunomodulatory pharmaceuticals combined with nbUV-B phototherapy demonstrated enhanced repigmentation by leveraging the potential additive or even synergistic effects of both treatments.” —Emma Guttman, MD, PhD, chair of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York, New York²³

Upadacitinib (AbbVie): Positive phase 3
results suggest oral JAK inhibition may become a mainstay.

As we move into 2026, dermatology stands on the brink of even greater innovation, with numerous late-stage trials poised to redefine standards of care. Advances in immunomodulation, gene therapy, and noninvasive treatment delivery are converging to create a future in which many chronic or previously untreatable conditions may finally achieve sustained remission. The breakthroughs of 2025 underscore a broader trend toward targeted, durable, and patient-centered care, laying the groundwork for continued progress and improved quality of life for patients worldwide.

References

1. Dupixent (dupilumab) approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria (CSU). News release. Regeneron Pharmaceuticals. April 18, 2025. Accessed November 10, 2025. https://www.globenewswire.com/news-release/2025/04/18/3064133/0/en/Dupixent-dupilumab-Approved-in-the-U-S-as-the-First-New-Targeted-Therapy-in-Over-a-Decade-for-Chronic-Spontaneous-Urticaria-CSU.html
2. US FDA approves Zevaskyn (prademagene zamikeracel), the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB). News release. Abeona Therapeutics. April 29, 2025. Accessed November 10, 2025. https://investors.abeonatherapeutics.com/press-releases/detail/303/u-s-fda-approves-zevaskyn-prademagene-zamikeracel
3. Sun Pharma announces FDA approval of next generation BLU-U Blue Light Photodynamic Therapy Illuminator for actinic keratosis. News release. Sun Pharma. May 16, 2025. Accessed November 10, 2025. https://www.prnewswire.com/news-releases/sun-pharma-announces-fda-approval-of-next-generation-blu-u-blue-light-photodynamic-therapy-illuminator-for-actinic-keratosis-302457770.html
4. Arcutis’ Zoryve (roflumilast) topical foam 0.3% approved by US FDA for the treatment of plaque psoriasis in adults and adolescents ages 12 and older. News release. Arcutis Biotherapeutics. May 22, 2025. Accessed November 10, 2025. https://www.arcutis.com/arcutis-zoryve-roflumilast-topical-foam-0-3-approved-by-u-s-fda-for-the-treatment-of-plaque-psoriasis-in-adults-and-adolescents-ages-12-and-older/
5. Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid. News release. Sanofi. June 20, 2025. Accessed November 10, 2025. https://www.sanofi.com/en/media-room/press-releases/2025/2025-06-20-05-00-00-3102518
6. Anzupgo (delgocitinib) cream is now the first and only FDA-approved treatment for moderate-to-severe chronic hand eczema (CHE) in adults. News release. LEO Pharma. July 23, 2025. Accessed November 10, 2025. https://www.businesswire.com/news/home/20250723115252/en/ANZUPGO-delgocitinib-Cream-Is-Now-the-First-and-Only-FDA-Approved-Treatment-for-Moderate-to-Severe-Chronic-Hand-Eczema-CHE-in-Adults
7. Incyte announces additional FDA approval of Opzelura (ruxolitinib) cream in children ages 2-11 with atopic dermatitis. News release. Incyte. September 18, 2025. Accessed November 10, 2025. https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib
8. US FDA approves Tremfya (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor. News release. Johnson & Johnson. September 29, 2025. Accessed November 10, 2025. https://www.jnj.com/media-center/press-releases/u-s-fda-approves-tremfya-guselkumab-for-the-treatment-of-pediatric-plaque-psoriasis-and-active-psoriatic-arthritis-marking-a-first-and-only-approval-for-an-il-23-inhibitor
9. Novartis receives FDA approval for Rhapsido (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU). News release. Novartis. September 30, 2025. Accessed November 10, 2025. https://www.globenewswire.com/news-release/2025/09/30/3159065/0/en/Novartis-receives-FDA-approval-for-Rhapsido-remibrutinib-the-only-oral-targeted-BTKi-treatment-for-chronic-spontaneous-urticaria-CSU.html
10. FDA approves Arcutis’ Zoryve (roflumilast) cream 0.05% for the treatment of atopic dermatitis in children ages 2 to 5. News release. Arcutis Biotherapeutics. October 6, 2025. Accessed November 10, 2025. https://www.globenewswire.com/news-release/2025/10/06/3161656/0/en/FDA-Approves-Arcutis-ZORYVE-roflumilast-Cream-0-05-for-the-Treatment-of-Atopic-Dermatitis-in-Children-Ages-2-to-5.html
11. Libtayo (cemiplimab-rwlc) approved in the US as first and only immunotherapy for adjuvant treatment of cutaneous squamous cell carcinoma (CSCC) with a high risk of recurrence after surgery and radiation. News release. Regeneron Pharmaceuticals. October 8, 2025. Accessed November 10, 2025. https://investor.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-rwlc-approved-us-first-and-only
12. CAGE Bio reports strong results from its phase 2b atopic dermatitis trial. News release. CAGE Bio. September 4, 2025. Accessed November 11, 2025. https://www.prnewswire.com/news-releases/cage-bio-reports-strong-results-from-its-phase-2b-atopic-dermatitis-trial-302547128.html?tc=eml_cleartime
13. Andrus E, Zalevsky J. Nektar’s Jonathan Zalevsky, PhD, dives into rezpegaldesleukin fast track designation for atopic dermatitis. Dermatology Times. February 14, 2025. Accessed November 11, 2025. https://www.dermatologytimes.com/view/nektar-s-jonathan-zalevsky-phd-dives-into-rezpegaldesleukin-fast-track-designation-for-atopic-dermatitis
14. Q32 Bio announces FDA fast track designation granted to bempikibart (ADX-914) for the treatment of alopecia areata. Q32 Bio. April 30, 2025. Accessed November 11, 2025. https://www.prnewswire.com/news-releases/q32-bio-announces-fda-fast-track-designation-granted-to-bempikibart-adx-914-for-the-treatment-of-alopecia-areata-302441850.html
15. Lilly’s baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in phase 3 BRAVE-AA-PEDS trial. News release. Eli Lilly and Company. October 24, 2025. Accessed November 11, 2025. https://www.prnewswire.com/news-releases/lillys-baricitinib-delivered-near-complete-scalp-hair-regrowth-at-one-year-for-adolescents-with-severe-alopecia-areata-in-phase-3-brave-aa-peds-trial-302593426.html
16. Incyte announces new 24-week phase 3 data from the STOP-HS clinical trial program of povorcitinib in hidradenitis suppurativa at EADV 2025. News release. Incyte. September 17, 2025. Accessed November 11, 2025. https://investor.incyte.com/news-releases/news-release-details/incyte-announces-new-24-week-phase-3-data-stop-hs-clinical-trial
17. Avalo Therapeutics announces completion of enrollment in phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa. News release. Avalo Therapeutics. October 29, 2025. Accessed November 11, 2025. https://www.globenewswire.com/news-release/2025/10/29/3176254/0/en/Avalo-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-2-LOTUS-Trial-of-AVTX-009-for-the-Treatment-of-Hidradenitis-Suppurativa.html
18. Ascletis announces US FDA clearance of IND application for its oral small molecule IL-17 inhibitor, ASC50, for the treatment of psoriasis. News release. Ascletis Pharma. May 22, 2025. Accessed November 11, 2025. https://www.prnewswire.com/news-releases/ascletis-announces-us-fda-clearance-of-ind-application-for-its-oral-small-molecule-il-17-inhibitor-asc50-for-the-treatment-of-psoriasis-302462995.html
19. Lockshin B, Hebebrand M. Second generation TYK2 inhibitors transform psoriasis management. Dermatology Times. October 26, 2025. Accessed November 11, 2025. https://www.dermatologytimes.com/view/second-generation-tyk2-inhibitors-transform-psoriasis-management
20. Hebebrand M, McGuire K. Karen McGuire, PhD, on advancing TAMES-02 trial for EB simplex. Dermatology Times. August 20, 2025. Accessed November 11, 2025. https://www.dermatologytimes.com/view/karen-mcguire-phd-on-advancing-tames-02-trial-for-eb-simplex
21. Milhem MM, Zakharia Y, Davar D, et al. Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: final analysis from a phase 1b study. Cancer. 2025;131(15):e70022. doi:10.1002/cncr.70022
22. Medicus Pharma Ltd announces positively trending interim analysis for SKNJCT-003 phase 2 clinical study to non-invasively treat basal cell carcinoma of the skin (BCC). News release. Medicus Pharma. March 6, 2025. Accessed November 11, 2025. https://medicuspharma.com/medicus-pharma-ltd-announces-positively-trending-interim-analysis-for-sknjct-003-phase-2-clinical-study-to-non-invasively-treat-basal-cell-carcinoma-of-the-skin-bcc/
23. Guttman-Yassky E. Oral ritlecitinib plus nbUV-B accelerates repigmentation in nonsegmental vitiligo. Dermatology Times. June 17, 2025. Accessed November 11, 2025. https://www.dermatologytimes.com/view/oral-ritlecitinib-plus-nbuv-b-accelerates-repigmentation-in-nonsegmental-vitiligo